AbbVie
ABBV
Biotechnology
- Revenue
- $61.2B
- Op. margin
- 24.7%
- FCF margin
- 29.1%
Companies
Search, filter and compare every US company we cover.
Sector
Health Care
No matches for “”.
Industry
Biotechnology
Health Care
No matches for “”.
Size
Any size
No matches for “”.
Today
Up or down
No matches for “”.
Add filter
Size
Growth
Margins
Returns
Debt and payouts
Valuation and quality
Insiders
No matches for “”.
Market cap
Price
Day change
Revenue
Revenue growth
Operating margin
P/E
5-yr growth
Gross margin
Net margin
Free cash flow
FCF margin
Return on capital
Return on equity
Net debt
Net debt / EBITDA
Dividends + buybacks
Share count change
F-score
Insider buys (90d)
Insider sales (90d)
| Company | Industry | Market cap | Price | Day change | Revenue | Revenue growth | Operating margin | P/E | 5-yr growth | Gross margin | Net margin | Free cash flow | FCF margin | Return on capital | Return on equity | Net debt | Net debt / EBITDA | Dividends + buybacks | Share count change | F-score | Insider buys (90d) | Insider sales (90d) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology | $507.2B | $286.39 | 0.1% | $61.2B | 8.6% | 24.7% | 80.9x | 6.0% | 70.2% | 6.9% | $17.8B | 29.1% | 15.7% | — | $61.8B | 2.7x | $12.6B | 0.0% | 7 | $0.0M | $8.2M | |
| Biotechnology | $243.7B | $447.95 | 0.7% | $36.8B | 10.0% | 24.7% | 27.8x | 7.7% | 67.3% | 21.0% | $8.1B | 22.0% | 14.4% | 106.1% | $45.5B | 3.2x | $5.1B | 0.2% | 7 | $0.0M | $4.1M | |
| Biotechnology | $197.7B | $159.08 | 0.2% | $29.4B | 2.4% | 34.0% | — | 3.6% | 78.8% | 28.9% | $9.5B | 32.1% | 23.0% | 40.5% | $17.3B | 1.4x | $5.9B | 0.0% | 8 | $0.0M | $15.9M | |
| Biotechnology | $133.0B | $521.03 | 0.7% | $12.0B | 8.9% | 34.8% | 30.3x | 14.1% | 86.2% | 32.9% | $3.2B | 26.6% | 31.5% | 22.5% | −$6.5B | −1.5x | $2.0B | 0.0% | 6 | $0.0M | $0.0M | |
| Biotechnology | $86.5B | $816.10 | 1.0% | $14.3B | 1.0% | 25.0% | 20.2x | 11.0% | — | 31.4% | $4.1B | 28.5% | 12.7% | 14.9% | −$5.9B | −1.4x | $3.8B | −5.7% | 5 | $0.0M | $6.5M | |
| Biotechnology | $82.8B | $207.97 | 4.6% | $1.9B | −39.9% | −158.1% | — | 19.3% | 55.4% | −145.2% | −$2.1B | −106.2% | −65.4% | −28.9% | −$5.2B | — | $2.0M | 1.3% | 2 | $0.0M | $62.6M | |
| Biotechnology | $37.5B | $252.73 | 0.2% | $9.9B | 2.2% | — | 27.2x | −6.0% | 75.7% | 13.1% | $2.1B | 20.7% | 7.3% | 7.4% | $2.5B | 1.0x | $0.0M | 0.8% | 5 | $0.0M | $0.2M | |
| Biotechnology | $27.1B | $591.20 | 0.3% | $3.2B | 10.6% | 46.9% | 21.2x | 16.5% | 87.9% | 41.9% | $1.0B | 32.7% | — | 19.7% | — | — | $1.0B | −1.2% | — | $0.0M | $327M | |
| Biotechnology | $26.3B | $36.54 | 1.4% | $8.3M | −71.6% | −6,235.7% | — | −19.0% | — | −3,629.2% | −$759M | −9,183.5% | −62.6% | −6.5% | −$4.3B | — | $0.0M | −4.4% | 1 | $0.0M | $59.9M | |
| Biotechnology | $24.1B | $116.60 | 2.9% | $5.1B | 21.2% | 29.5% | 16.5x | 14.0% | 92.8% | 25.0% | $1.4B | 26.4% | 79.4% | 29.9% | −$3.5B | −2.2x | $0.0M | −4.7% | 8 | $0.0M | $15.0M | |
| Biotechnology | $17.0B | $65.35 | 0.4% | $2.3B | 7.0% | 37.6% | 20.6x | 18.6% | 96.4% | 33.7% | $876M | 37.8% | 64.9% | 35.5% | −$1.1B | −1.2x | $948M | −4.8% | 6 | $0.0M | $0.5M | |
| Biotechnology | $15.6B | $128.50 | 0.4% | $1.4B | 37.6% | 33.6% | 37.5x | 39.2% | 83.6% | 22.7% | $645M | 46.2% | 19.2% | 153.6% | $2.0B | 4.2x | $342M | −4.3% | 5 | $0.0M | $22.1M | |
| Biotechnology | $15.2B | $146.00 | 0.1% | $2.9B | 21.5% | 21.6% | 21.4x | 22.3% | 98.2% | 16.7% | $749M | 26.2% | 25.6% | 16.4% | −$1.5B | −2.3x | $168M | −1.2% | 6 | $0.0M | $0.8M | |
| Biotechnology | $10.8B | $55.35 | 0.7% | $3.2B | 12.9% | 12.7% | 149.6x | 11.6% | 77.7% | 10.8% | $725M | 22.5% | 5.8% | 5.9% | −$963M | −2.0x | $0.0M | 0.4% | 5 | $0.0M | $1.2M | |
| Biotechnology | $9.8B | $320.58 | 2.2% | $389M | 33.9% | 41.5% | 40.2x | — | — | 52.6% | $189M | 48.6% | 43.6% | 18.9% | −$828M | −5.0x | $0.0M | 0.7% | 5 | $0.0M | $26.2M | |
| Biotechnology | $8.5B | $59.03 | 0.1% | $829M | 23,258.2% | 11.9% | — | 56.6% | — | −0.2% | $157M | 18.9% | — | −0.5% | −$665M | −5.5x | $0.0M | 11.7% | 5 | $0.0M | $1.2M | |
| Biotechnology | $6.8B | $311.73 | 1.1% | $268M | 60.4% | 15.3% | 33.1x | 10.4% | — | 46.4% | $48.9M | 18.2% | 4.9% | 13.5% | −$287M | −3.8x | $15.0M | 11.0% | 5 | $0.0M | $16.1M | |
| Biotechnology | $2.6B | $11.17 | 0.9% | $510M | 19.6% | 37.5% | 16.0x | 64.6% | 57.4% | 28.8% | $27.8M | 5.5% | 39.5% | 35.6% | −$15.5M | −0.1x | $31.9M | 0.6% | 5 | $0.0M | $0.0M | |
| Biotechnology | $2.3B | $24.43 | 2.5% | $2.7B | 1.0% | −32.0% | — | — | — | −36.2% | $88.3M | 3.2% | −36.2% | −102.4% | $878M | — | $0.0M | — | — | $0.0M | $4.3M | |
| Biotechnology | $2.2B | $37.95 | 3.0% | $869M | 21.5% | 24.0% | 12.3x | 40.3% | 77.2% | 18.3% | $348M | 40.1% | 48.9% | 20.8% | −$612M | — | $0.0M | 1.2% | 5 | $0.0M | $3.1M | |
| Biotechnology | — | $175.80 | 2.4% | $738M | 16.4% | 7.5% | — | 15.1% | 52.3% | 6.6% | $93.9M | 12.7% | 2.4% | 2.4% | −$225M | −1.7x | $0.0M | — | — | $0.0M | $6.0M | |
| Biotechnology | — | $61.52 | 1.3% | $88.0M | 376.6% | −695.4% | — | 9.5% | — | −891.6% | −$535M | −607.5% | — | — | −$912M | — | $0.0M | — | — | $0.0M | $12.9M |
Amgen
AMGN
Biotechnology
- Revenue
- $36.8B
- Op. margin
- 24.7%
- FCF margin
- 22.0%
- Revenue
- $29.4B
- Op. margin
- 34.0%
- FCF margin
- 32.1%
- Revenue
- $12.0B
- Op. margin
- 34.8%
- FCF margin
- 26.6%
- Revenue
- $14.3B
- Op. margin
- 25.0%
- FCF margin
- 28.5%
Moderna
MRNA
Biotechnology
- Revenue
- $1.9B
- Op. margin
- −158.1%
- FCF margin
- −106.2%
Biogen
BIIB
Biotechnology
- Revenue
- $9.9B
- Net margin
- 13.1%
- FCF margin
- 20.7%
- Revenue
- $3.2B
- Op. margin
- 46.9%
- FCF margin
- 32.7%
- Revenue
- $8.3M
- Op. margin
- −6,235.7%
- FCF margin
- −9,183.5%
Incyte
INCY
Biotechnology
- Revenue
- $5.1B
- Op. margin
- 29.5%
- FCF margin
- 26.4%
Exelixis
EXEL
Biotechnology
- Revenue
- $2.3B
- Op. margin
- 37.6%
- FCF margin
- 37.8%
Halozyme
HALO
Biotechnology
- Revenue
- $1.4B
- Op. margin
- 33.6%
- FCF margin
- 46.2%
- Revenue
- $2.9B
- Op. margin
- 21.6%
- FCF margin
- 26.2%
- Revenue
- $3.2B
- Op. margin
- 12.7%
- FCF margin
- 22.5%
- Revenue
- $389M
- Op. margin
- 41.5%
- FCF margin
- 48.6%
- Revenue
- $829M
- Op. margin
- 11.9%
- FCF margin
- 18.9%
- Revenue
- $268M
- Op. margin
- 15.3%
- FCF margin
- 18.2%
- Revenue
- $510M
- Op. margin
- 37.5%
- FCF margin
- 5.5%
Fortrea
FTRE
Biotechnology
- Revenue
- $2.7B
- Op. margin
- −32.0%
- FCF margin
- 3.2%
- Revenue
- $869M
- Op. margin
- 24.0%
- FCF margin
- 40.1%
Repligen
RGEN
Biotechnology
- Revenue
- $738M
- Op. margin
- 7.5%
- FCF margin
- 12.7%
- Revenue
- $88.0M
- Op. margin
- −695.4%
- FCF margin
- −607.5%
What do these columns mean?
- Market cap
- Last close times the latest diluted share count, so it is approximate.
- Price
- Closing share price on the last trading day.
- Day change
- Change in the closing price against the previous trading day's close.
- Revenue
- Total sales reported in the income statement.
- Revenue growth
- Change in revenue against the year (or quarter) a year earlier.
- Operating margin
- Operating income as a share of revenue.
- P/E
- Last close divided by diluted earnings per share over the last four quarters.
- 5-yr growth
- Revenue growth a year, compounded over the last five years.
- Gross margin
- Gross profit as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Free cash flow
- Cash from operations minus capital spending.
- FCF margin
- Free cash flow as a share of revenue.
- Return on capital
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
- Return on equity
- Net income as a share of average shareholders' equity.
- Net debt
- Debt and finance leases minus cash and short-term investments. Negative means net cash.
- Net debt / EBITDA
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Dividends + buybacks
- Cash returned to shareholders through dividends and share repurchases.
- Share count change
- Change in the diluted share count. Negative means buybacks shrank it.
- F-score
- Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
- Industry
- The industry the company reports under, from its SEC filing code. Click it to see its peers.
- Colours and dashes
- Green is up or growing, red is down or shrinking. — means no data, or a P/E that is not meaningful (losses, or above 200).
- Units
- M = millions, B = billions, T = trillions, in USD. Fundamentals use the latest fiscal year. Use “Edit columns” to show more figures, hide some or change their order.